While I realize that you will never believe me, nonetheless it should be stated that adaptive trial designs do not save alpha spend except to the extent that:
You're right. We're going to have to agree it disagree on this one.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr